This company is no longer active
The company may no longer be operating, as it may be out of business. Find out why through their latest events.
Gemini Therapeutics Past Earnings Performance
Past criteria checks 0/6
Key information
-22.0%
Earnings growth rate
46.0%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -41.5% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2022 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
Revenue & Expenses Breakdown
BetaHow Gemini Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 22 | 0 | -43 | 17 | 24 |
| 30 Jun 22 | 0 | -59 | 19 | 37 |
| 31 Mar 22 | 0 | -68 | 20 | 45 |
| 31 Dec 21 | 0 | -72 | 20 | 48 |
| 30 Sep 21 | 0 | -68 | 17 | 44 |
| 30 Jun 21 | 0 | -60 | 14 | 37 |
| 31 Mar 21 | 0 | -50 | 9 | 32 |
| 31 Dec 20 | 0 | -41 | 6 | 28 |
| 30 Sep 20 | 0 | -36 | 5 | 29 |
| 30 Jun 20 | 0 | -37 | 6 | 30 |
| 31 Mar 20 | 0 | -41 | 7 | 34 |
| 31 Dec 19 | 0 | -41 | 7 | 34 |
Quality Earnings: GMTX is currently unprofitable.
Growing Profit Margin: GMTX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: GMTX is unprofitable, and losses have increased over the past 5 years at a rate of 22% per year.
Accelerating Growth: Unable to compare GMTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GMTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (53%).
Return on Equity
High ROE: GMTX has a negative Return on Equity (-41.52%), as it is currently unprofitable.